21.Wk2Assgn

As an advanced practice nurse, it is your responsibility to recommend appropriate treatment options for patients with cardiovascular disorders. To ensure the safety and effectiveness of drug therapy, advanced practice nurses must consider aspects that might influence pharmacokinetic and pharmacodynamic processes such as medical history, other drugs currently prescribed, and individual patient factors.

To Prepare

Review the Resources for this module and consider the impact of potential pharmacotherapeutics for cardiovascular disorders introduced in the media piece.

Review the case study assigned by your Instructor for this Assignment

(Patient Case:

Patient HM has a history of atrial fibrillation and a transient ischemic attack (TIA). The patient has been diagnosed with type 2 diabetes, hypertension, hyperlipidemia and ischemic heart disease. Drugs currently prescribed include the following: eview the case study assigned by your Instructor for this Assignment.)

Select one the following factors: genetics, gender, ethnicity, age, or behavior factors.

Reflect on how the factor you selected might influence the patient’s pharmacokinetic and pharmacodynamic processes.

Consider how changes in the pharmacokinetic and pharmacodynamic processes might impact the patient’s recommended drug therapy.

Think about how you might improve the patient’s drug therapy plan based on the pharmacokinetic and pharmacodynamic changes. Reflect on whether you would modify the current drug treatment or provide an alternative treatment option for the patient.

By Day 7 of Week 2

Write a 2- to 3-page paper that addresses the following:

Explain how the factor you selected might influence the pharmacokinetic and pharmacodynamic processes in the patient from the case study you were assigned.

Describe how changes in the processes might impact the patient’s recommended drug therapy. Be specific and provide examples.

Explain how you might improve the patient’s drug therapy plan and explain why you would make these recommended improvements.

*******There is an additional requirement for Week 2. *********

A list of the patient's current drugs is provided, after you've made changes to the drug list, you are required to provide a Revised Drug List.

Read Week 2 Module Requirements.

Write a 2- to 3-page paper that addresses the following: Describe how changes in the processes might impact the patient’s recommended drug therapy, Be specific and provide examples..

Explain how you might improve the patient’s drug therapy plan and explain why you would make these recommended improvements.

Patient Case:

Patient HM has a history of atrial fibrillation and a transient ischemic attack (TIA). The patient has been diagnosed with type 2 diabetes, hypertension, hyperlipidemia and ischemic heart disease. Drugs currently prescribed include the following:

Current Drug List:

Warfarin 5 mg daily MWF and 2.5 mg daily T, TH, Sat, Sun

Aspirin 81 mg daily

Metformin 1000 mg po bid

Glyburide 10 mg bid

Atenolol 100 mg po daily

Motrin 200 mg 1–3 tablets every 6 hours as needed for pain

Make sure your drug changes are provided as a drug list format, similar to the patient's current drug list.

Provide an explanation for the drug changes to the patient's current list.

You may use more than (3) pages for all posts in this class.

-The only source they offered was my textbook. So please find a couple on your own

Rosenthal, L. D., & Burchum, J. R. (2018). Lehne’s pharmacotherapeutics for advanced practice providers. St. Louis, MO: Elsevier.

Chapter 34, “Review of Hemodynamics” (pp. 335–340)

Chapter 35, “Diuretics” (pp. 341–349)

Chapter 36, “Drugs Acting on the Renin-Angiotensin-Aldosterone System” (pp. 351–362)

Chapter 37, “Calcium Channel Blockers” (pp. 363–369)

Chapter 38, “Vasodilators” (pp. 371–373)

Chapter 39, “Drugs for Hypertension” (pp. 375–388)

Chapter 40, “Drugs for Heart Failure” (pp. 389–402)

Chapter 41, “Antidysrhythmic Drugs” (pp. 403–418)

Chapter 42, “Prophylaxis of Atherosclerotic Cardiovascular Disease: Drugs That Help Normalize Cholesterol and Triglyceride Levels” (pp. 419–439)

Chapter 43, “Drugs for Angina Pectoris” (pp. 441–450)

Chapter 44, “Anticoagulant and Antiplatelet Drugs” (pp. 451–472)